Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 391-401

  Ferguson, Rosalyn D ^a   Gallagher, Emily J ^a   Cohen, Dara ^a   Tobin Hess, Aviva ^a   Alikhani, Nyosha ^a   Novosyadlyy, Ruslan ^a   Haddad, Nadine ^a   Yakar, Shoshana ^a   LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Type 2 diabetes

Indexed keywords

DOXYCYCLINE; DRINKING WATER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INSULIN; SOMATOMEDIN C RECEPTOR; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE OVEREXPRESSION; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION;

BREAST CANCER; TYPE 2 DIABETES;

ANIMALS; HUMANS; HYPERINSULINISM; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; RECEPTOR, ERBB-2;

EID: 84879490997     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0333     Document Type: Article

References (44)

1. Baselga J & Swain SM 2010 CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clinical Breast Cancer 10 489-491. (doi:10.3816/CBC.2010.n.065)
2. Bollig-Fischer A, Dewey TG & Ethier SP 2011 Oncogene activation induces metabolic transformation resulting in insulin-independence in human breast cancer cells. PLoS ONE 6 e17959. (doi:10.1371/journal.pone. 0017959)
3. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, Fairley LL, Zheng T, Zhang Y, Pasterk M et al. 2012 Diabetes and breast cancer risk: a meta-analysis. British Journal of Cancer 107 1608-1617. (doi:10.1038/bjc.2012.414)
4. Calle EE & Kaaks R 2004 Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer 4 579-591. (doi:10.1038/nrc1408)
5. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr & Leahy DJ 2003 Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 756-760. (doi:10.1038/nature01392)
6. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R & McTiernan A 2011 Associations of insulin resistance and adiponectin with mortality in women with breast cancer. Journal of Clinical Oncology 29 32-39. (doi:10.1200/JCO.2009.26. 4473)
7. Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S & Leroith D 2012 Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Research 14 R8. (doi:10.1186/bcr3089)
8. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S & LeRoith D 2010 Insulinsensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59 686-693. (doi:10.2337/db09-1291)
9. Formica V, Tesauro M, Cardillo C & Roselli M 2012 Insulinemia and the risk of breast cancer and its relapse. Diabetes, Obesity & Metabolism 14 1073-1080.
10. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW et al. 2003 The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molecular Cell 11 495-505. (doi:10.1016/S1097- 2765(03)00048-0)
11. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P & Foidart JM 2003 Transactivation of vimentin by β-catenin in human breast cancer cells. Cancer Research 63 2658-2664.
12. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B & Hood N 2002 Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. Journal of Clinical Oncology 20 42-51. (doi:10.1200/JCO.20.1.42)
13. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK & Hood N 2012 Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. Journal of Clinical Oncology 30 164-171. (doi:10.1200/JCO.2011.36.2723)
14. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL et al. 2009 Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 101 48-60. (doi:10.1093/jnci/djn415)
15. Harari D & Yarden Y 2000 Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19 6102-6114. (doi:10.1038/sj.onc. 1203973)
16. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH & Yeung SC 2012 Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Annals of Oncology 23 1771-1780. (doi:10.1093/annonc/mdr534)
17. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, III & Hynes NE 2003 The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. PNAS 100 8933-8938. (doi:10.1073/pnas.1537685100)
18. Huang J, Morehouse C, Streicher K, Higgs BW, Gao J, Czapiga M, Boutrin A, Zhu W, Brohawn P, Chang Y et al. 2011 Altered expression of insulin receptor isoforms in breast cancer. PLoS ONE 6 e26177. (doi:10.1371/journal.pone.0026177)
19. Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L & Ballard-Barbash R 2011 Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. Journal of Clinical Oncology 29 47-53. (doi:10.1200/JCO.2010.28.4752)
20. Jin Q & Esteva FJ 2008 Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 485-498. (doi:10.1007/s10911- 008-9107-3)
21. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW & Waltham M 2007 Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and In vivo. Cells, Tissues, Organs 185 191-203. (doi:10.1159/000101320)
22. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt B, Boecker W & Buerger H 2005 The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? Journal of Pathology 206 451-457. (doi:10.1002/path.1797)
23. Larsson SC, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer 121 856-862. (doi:10.1002/ijc.22717)
24. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE et al. 2008 Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68 10238-10246. (doi:10.1158/0008- 5472.CAN-08-2755)
25. Lu Y, Zi X, Zhao Y, Mascarenhas D & Pollak M 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute 93 1852-1857. (doi:10.1093/jnci/93.24.1852)
26. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L et al. 2004 Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. Journal of Biological Chemistry 279 2856-2865. (doi:10.1074/jbc.M310132200)
27. Luijten M, Verhoef A, Dormans JA, Beems RB, Cremers HW, Nagelkerke NJ, Adlercreutz H, Penalvo JL & Piersma AH 2007 Modulation ofmammary tumor development in Tg.NK (MMTV/c-neu) mice by dietary fatty acids and life stage-specific exposure to phytoestrogens. Reproductive Toxicology 23 407-413. (doi:10.1016/j.reprotox.2006.12.001)
28. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD & Chodosh LA 2002 Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2 451-461. (doi:10.1016/S1535-6108(02)00212-X)
29. Nahta R, Yu D, Hung MC, Hortobagyi GN & Esteva FJ 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice. Oncology 3 269-280. (doi:10.1038/ncponc0509)
30. Novosyadlyy R & LeRoith D 2010 Hyperinsulinemia and type 2 diabetes: impact on cancer. Cell Cycle 9 1449-1450. (doi:10.4161/cc.9.8.11512)
31. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA et al. 2010 Insulinmediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Research 70 741-751. (doi:10.1158/0008-5472.CAN-09- 2141)
32. Osborne CK, Monaco ME, Lippman ME & Kahn CR 1978 Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Research 38 94-102.
33. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL & Wolff AC 2011 Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. Journal of Clinical Oncology 29 40-46. (doi:10.1200/JCO.2009.27.3011)
34. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ & Yarden Y 1996 Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. Journal of Biological Chemistry 271 19029-19032. (doi:10.1074/jbc.271.32.19029)
35. Pisani P 2008 Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Archives of Physiology and Biochemistry 114 63-70. (doi:10.1080/13813450801954451)
36. Satelli A & Li S 2011 Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and Molecular Life Sciences 68 3033-3046. (doi:10.1007/s00018-011-0735-1)
37. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V & Kitchen P 1993 Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. Journal of Clinical Oncology 11 1936-1942.
38. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al. 1989 Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244 707-712. (doi:10.1126/science. 2470152)
39. Soon PS, Kim E, Pon CK, Gill AJ, Moore K, Spillane AJ, Benn DE & Baxter RC 2013 Breast cancer-associated fibroblasts induce epithelial-to- mesenchymal transition in breast cancer cells. Endocrine-Related Cancer 20 1-12. (doi:10.1530/ERC-12-0227)
40. Sugimoto H, Mundel TM, Kieran MW & Kalluri R 2006 Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biology & Therapy 5 1640-1646. (doi:10.4161/cbt.5.12.3354)
41. Ursini-Siegel J, Schade B, Cardiff RD & Muller WJ 2007 Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews. Cancer 7 389-397. (doi:10.1038/nrc2127)
42. Yarden Y 2001 Biology of HER2 and its importance in breast cancer. Oncology 61 (Suppl 2) 1-13. (doi:10.1159/000055396)
43. Zeisberg M & Neilson EG 2009 Biomarkers for epithelial-mesenchymal transitions. Journal of Clinical Investigation 119 1429-1437. (doi:10.1172/JCI36183)
44. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D & Yee D 2010 Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 29 2517-2527. (doi:10.1038/onc.2010.17)